source
- Tango and Revolution report high response rates in early pancreatic cancer combo trialTango Therapeutics and Revolution Medicines tested a combination of Tango's drug vopimetostat with Revolution's daraxonrasib in an early-stage clinical trial for pancreatic cancer. The study enroll…
- Biopharma must pair innovation with operational readiness to scale therapiesThe article argues that breakthrough science alone no longer guarantees success in biopharma. Companies now face pressure to turn discoveries into reliably manufactured, delivered, and scalable pro…